Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
478 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
705 Views
Health & Happiness: Not that Healthy After All and May Lead to Unhappy Shareholders?
Post the disclosure of the agreement that Swisse made with a JV that is owned by Procter & Gamble Co/The (PG US) and Teva Pharmaceutical Sp Adr...
360 Views
Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
145 Views
US Healthcare Overhaul Stumbling, Singapore Cyclical Rally Looking Premature
The Republican replacement for ‘Obamacare’ has been announced and looks an incoherent mess – resurgent healthcare inflation will be a drag on...
1.6k Views